Insider Selling: Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Director Sells 5,740 Shares of Stock

Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) Director Shamim Ruff sold 5,740 shares of the company’s stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $83.73, for a total transaction of $480,610.20. Following the transaction, the director now owns 5,223 shares in the company, valued at approximately $437,321.79. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Reata Pharmaceuticals Price Performance

Shares of NASDAQ:RETA opened at $84.36 on Wednesday. Reata Pharmaceuticals, Inc. has a 1-year low of $18.47 and a 1-year high of $95.00. The business has a 50-day moving average price of $50.82 and a two-hundred day moving average price of $38.66.

Analysts Set New Price Targets

Several brokerages recently issued reports on RETA. Cantor Fitzgerald upped their price target on shares of Reata Pharmaceuticals from $61.00 to $121.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 1st. SVB Securities upped their price target on shares of Reata Pharmaceuticals from $35.00 to $75.00 in a research report on Wednesday, March 1st. Citigroup upped their price target on shares of Reata Pharmaceuticals from $53.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, March 1st. Stifel Nicolaus upped their price target on shares of Reata Pharmaceuticals from $75.00 to $105.00 in a research report on Wednesday, March 1st. Finally, Barclays upped their price target on shares of Reata Pharmaceuticals from $50.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Reata Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.00.

Institutional Trading of Reata Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in RETA. Point72 Asset Management L.P. bought a new stake in Reata Pharmaceuticals during the 3rd quarter worth about $45,502,000. First Light Asset Management LLC bought a new stake in shares of Reata Pharmaceuticals in the 3rd quarter valued at about $26,512,000. Fred Alger Management LLC increased its stake in shares of Reata Pharmaceuticals by 146.7% in the 4th quarter. Fred Alger Management LLC now owns 1,509,404 shares of the company’s stock valued at $57,342,000 after acquiring an additional 897,481 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Reata Pharmaceuticals by 46.4% in the 4th quarter. Deutsche Bank AG now owns 1,492,238 shares of the company’s stock valued at $56,690,000 after acquiring an additional 472,726 shares during the last quarter. Finally, Morgan Stanley increased its stake in shares of Reata Pharmaceuticals by 134.2% in the 4th quarter. Morgan Stanley now owns 733,732 shares of the company’s stock valued at $27,874,000 after acquiring an additional 420,490 shares during the last quarter. 76.13% of the stock is owned by institutional investors.

Reata Pharmaceuticals Company Profile

(Get Rating)

Reata Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.